Isomorphic Labs vs Recursion Pharmaceuticals

Isomorphic Labs — Application · Private · $2.7B raised · 2 of 2 figures sourced  |  Recursion Pharmaceuticals — Application · Public · $1.9B mkt cap · 5 of 5 figures sourced

Relationship

Both are AI-native drug-discovery platforms — Recursion OS against Isomorphic's Drug Design Engine — named as rivals in Recursion's own 10-K.

1 of 1 capabilityShared product typeNamed in filingFind drug candidates faster

1 of 1 capability — Shares drug discovery.

Ludbee capability tags · from the product records

Shared product type — Both ship platform.

Ludbee product records

Named in filing — “Representative examples include Relay Therapeutics, Isomorphic Labs, Schrodinger, and AbCellera.”

sec.gov · checked 2026-02-25

Find drug candidates faster — Rivals on this job — Screen, design or predict molecules and biological structure to shorten early-stage drug discovery, not run a clinical trial.

Ludbee needs vocabulary · the scope on the sourced edge

Aligned comparison

FieldIsomorphic LabsRecursion Pharmaceuticals
Size$2.7B raised$1.9B mkt cap different basis
Employees—600
Founded20212013 8 yrs earlier
StatusPrivatePublic
CategoryApplicationApplication match
Stack layerPlatformPlatform match
HeadquartersLondon, United KingdomSalt Lake City, USA

Capability overlap

Shared · 1

Drug discovery

Identical capability tags — the difference is in execution, not scope.

Products, side by side

Hand-checked pairing

Isomorphic Labs

Platform

Drug Design EnginePlatform

Unified AI system, built on and beyond AlphaFold, that models drug candidates across small molecules and biologics for historically difficult targets. Used internally and through pharma co-development partnerships (e.g. Eli Lilly, Novartis) rather than sold directly.

Recursion Pharmaceuticals

Platform

Recursion OSPlatform

Drug-discovery platform combining automated cell-biology experiments with machine-learning models over the resulting data.

Open in the browser view